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activity in chronic multi-site musculoskeletal pain:
partly masked by depressive and anxiety disorders
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and Joost Dekker1,4Abstract
Background: Studies on hypothalamic-pituitary-adrenal axis (HPA-axis) function amongst patients with chronic pain
show equivocal results and well-controlled cohort studies are rare in this field. The goal of our study was to examine
whether HPA-axis dysfunction is associated with the presence and the severity of chronic multi-site musculoskeletal
pain.
Methods: Data are from the Netherlands Study of Depression and Anxiety including 1125 subjects with and without
lifetime depressive and anxiety disorders. The Chronic Pain Grade questionnaire was used to determine the presence
and severity of chronic multi-site musculoskeletal pain. Subjects were categorized into a chronic multi-site musculoskeletal
pain group (n = 471) and a control group (n = 654). Salivary cortisol samples were collected to assess HPA-axis function
(awakening level, 1-h awakening response, evening level, diurnal slope and post-dexamethasone level).
Results: In comparison with the control group, subjects with chronic multi-site musculoskeletal pain showed
significantly lower cortisol level at awakening, lower evening level and a blunted diurnal slope. Lower cortisol level at
awakening and a blunted diurnal slope appeared to be restricted to those without depressive and/or anxiety disorders,
who also showed a lower 1-h awakening response.
Conclusions: Our results suggest hypocortisolemia in chronic multi-site musculoskeletal pain. However, if chronic pain
is accompanied by a depressive or anxiety disorder, typically related to hypercortisolemia, the association between
cortisol levels and chronic multi-site musculoskeletal pain appears to be partly masked. Future studies should take
psychopathology into account when examining HPA-axis function in chronic pain.
Keywords: Hypothalamic-pituitary-adrenal axis, Salivary cortisol, Chronic pain, Central sensitization, PsychopathologyBackground
Chronic pain, usually defined as pain lasting longer than
three months [1], is common with population prevalence
estimates of ~10% [2] and results in reduced quality of
life [3]. Chronic pain rarely presents at a single body site,
it more often presents at multiple body locations, typic-
ally in the musculoskeletal system [4-6]. Compared to
single-site pain, multi-site musculoskeletal pain has been
associated with a greater negative impact on patients’* Correspondence: e.generaal@ggzingeest.nl
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unless otherwise stated.functioning [7] and disability [6,8], and an increased risk
of depressive and anxiety disorders [9]. Whereas acute
localized pain is often attributable primarily to damage
in the peripheral structures, chronic multi-site musculo-
skeletal pain can exist without any nociceptive input [1].
Existing interventions of chronic pain are at best moder-
ately effective [10,11] and although epidemiological stud-
ies have improved our knowledge on the etiology of
chronic pain, its underlying biological mechanisms are
still largely unclear.
Evidence suggests that chronic pain conditions may be
the consequence of increased neurotransmitter activity
of the central nervous system, a process called central
sensitization [12]. The hypothalamic-pituitary-adrenalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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likely involved in initiating and perpetuating this process
[12,13]. The nature of the relationship between HPA-
axis function and chronic pain is however far from fully
elucidated [14,15]. A few clinic-based studies (n < 50) in
patients with fibromyalgia found hyperactive HPA-axis
responses, loss of cortisol diurnal variation with elevated
evening cortisol levels [16,17] and increased sensitivity
to feedback inhibition of the HPA-axis [18]. Alterna-
tively, two other studies found basal serum cortisol levels
in fibromyalgia patients in the normal range [19,20].
However, the majority of previous studies (n < 100; one
larger study: n = 429) found reduced activity and im-
paired feedback sensitivity of the HPA-axis in chronic
pain conditions [13,19,21-26], mostly characterized by
low basal levels of cortisol as well as a blunted cortisol
response to a variety of stressors and dynamic tests. Al-
though evidence is limited, some studies found increased
salivary cortisol levels to be associated with higher pain
severity scores among subjects with chronic widespread
pain [27,28]. However, other studies found decreased cor-
tisol activity and reactivity to be associated with higher
pain severity among healthy controls [29] and among
chronic pain patients [30]. One prospective study found
that subjects with low morning and high evening salivary
cortisol levels, indicative of a blunting of the diurnal corti-
sol rhythm, and increased levels of serum cortisol after the
dexamethasone suppression test (DST), indicative of a fail-
ure to suppress the HPA-axis, were more likely to develop
new-onset chronic widespread pain [24].
Thus, although several studies have suggested a link
with HPA-axis dysfunction, whether the HPA-axis is
hypoactive or hyperactive in persons with chronic multi-
site musculoskeletal pain is yet undetermined. Moreover,
most previous studies were rather small in sample size
and did not consistently take possible confounders such
as lifestyle and disease factors into account. Furthermore,
depressive and anxiety disorders have not frequently been
considered as covariates that may confound the associ-
ation between chronic multi-site musculoskeletal pain and
HPA-axis function, although these disorders are prevalent
among persons with chronic pain and have often been as-
sociated with hypercortisolemia [31-34]. Therefore, the
present cross-sectional study investigated the hypothesis
that HPA-axis dysfunction is associated with the presence
and severity of chronic multi-site musculoskeletal pain,
while controlling for sociodemographics, lifestyle and dis-
ease factors and depressive and anxiety disorders.
Methods
Subjects
This cross-sectional study was based on data from the
Netherlands Study of Depression and Anxiety (NESDA),
an ongoing cohort study conducted among 2981 adults,aged between 18 and 65 years at the baseline assess-
ment. Subjects were recruited from the general popula-
tion (n = 564), general practices (n = 1610) and from
mental health care organizations (n = 807). People in dif-
ferent developmental stages of psychopathology as well
as controls with no psychiatric diagnosis participated.
The NESDA study contains a high proportion of sub-
jects with chronic multi-site musculoskeletal pain and
provides a unique opportunity to control for relevant
variables such as depressive and anxiety disorders. Fur-
ther details of the NESDA study have been described
elsewhere [35]. The research protocol was approved by
the Central Ethics Committee on Research Involving
Human Subjects of the VU University Medical Center
Amsterdam and all respondents provided written in-
formed consent.
From the initial 2981 respondents, 767 persons met
the criteria for the chronic multi-site musculoskeletal
pain group and 887 persons for the control group (cri-
teria discussed in measurements section below). Of these
subjects, 455 persons were excluded because no valid
salivary cortisol values were available and 74 persons be-
cause they used corticosteroids that are known to influ-
ence HPA-axis function. There were no pregnant or
breastfeeding women in our study sample, leaving a total
of 1125 subjects for our analyses (471 with chronic
multi-site musculoskeletal pain and 654 controls).
Excluded subjects (n = 529) were significantly younger
(40.2 vs. 44.7 years, p < 0.001), had fewer years of educa-
tion (11.6 vs. 12.4 years, p < 0.001), had more often
chronic multi-site musculoskeletal pain (56.0 vs. 41.9%,
p < 0.001) and had more often a lifetime depressive and/
or anxiety disorder (80.2 vs. 71.2%, p < 0.001), but did
not differ in sex, compared with included subjects (n =
1125). Differences in covariates between excluded and
included subjects were similar within the chronic pain
group and, apart from that, in the control group.
Chronic multi-site musculoskeletal pain
Chronic multi-site musculoskeletal pain was measured
using the Chronic Pain Grade (CPG) [36], a reliable and
valid measure of severity of chronic pain [37,38]. The
CPG first inquires about the presence of pain in the
prior six months on several locations (i.e., the extrem-
ities [joints of the arms, hands, legs or feet], back, neck,
head, abdomen, chest, and the mouth and face [orofacial
area]) [39]. The subsequent questions in the CPG refer
to the most painful location and include: 1) days in pain
in the prior six months (scale 0-180); 2) pain at this
moment (scale 0-10); 3) worst pain in the prior six months
(scale 0-10); 4) average pain in the prior six months (scale
0-10); 5) disability days in the prior six months (scale 0-
180); 6) disability in daily activities (scale 0-10); 7) disabil-
ity in spare time, social life, and family activities (scale 0-
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the CPG protocol, five grades were categorized from these
measures: grade 0 (pain free, no pain in the prior six
months); grade I (low disability, low intensity); grade II
(low disability, high intensity); grade III (high disability,
moderately limiting); and grade IV (high disability, se-
verely limiting).
The CPG was used to classify two groups. Subjects
were classified as having chronic multi-site musculoskel-
etal pain if they had grade I, II, III or IV and pain
present in (one or more of ) the extremities, and the
back and the neck (n = 471). For reasons of clarity, we
further refer to the chronic multi-site musculoskeletal
pain group as the chronic pain group. The control group
consisted of people with grade 0 (n = 130) or with grade
I and pain in the prior six months in at most 2 locations
(n = 524). The remaining subjects who did not meet the
criteria of the chronic pain group or the control group
were not eligible to be included in the present study (n =
1327). Of the total NESDA sample, approximately 26%
met criteria for chronic multi-site musculoskeletal pain.
For examination of pain severity, pain intensity and
pain disability were assessed in subjects with chronic
pain. For assessment of pain intensity, questions 2, 3 and
4 of the CPG were used (see above) to yield a total pain
intensity score (average of the 0-10 ratings of the 3 ques-
tions multiplied by 10 resulting in a 0-100 score) [36].
For assessment of pain disability, questions 6, 7 and 8 of
the CPG were used (see above) to yield a total pain dis-
ability score (average of the 0-10 ratings of the 3 ques-
tions multiplied by 10 resulting in a 0-100 score) [36].
HPA-axis function
As described in more detail elsewhere [40], respondents
collected saliva samples at home on a (regular) working
day shortly after the baseline interview. The median time
between the interview and saliva sampling was 9.0 days
(IQR: 5-22). Instructions prohibited eating, smoking,
drinking, or brushing teeth within 15 minutes before
sampling. Saliva samples were obtained using Salivettes
(Sarstedt AG and Co, Numbrecht, Germany) at seven
time points covering 1-h awakening cortisol, evening
values and a dexamethasone suppression test. The corti-
sol awakening response (CAR) includes four sampling
points: at awakening (T1) and 30 (T2), 45 (T3), and 60
(T4) minutes later. Two evening values were collected at
10 p.m. (T5) and 11 p.m. (T6). Dexamethasone suppres-
sion was measured by cortisol sampling the next morning
on awakening (T7) after ingestion of 0.5 mg dexametha-
sone, directly after the saliva sample at 11 p.m. (T6) was
taken. Samples were stored in refrigerators and returned
by mail. Cortisol analysis was performed by competitive
electrochemiluminescence immunoassay (E170 Roche,
Switzerland). The functional detection limit was 2.0 nmol/land the intra- and interassay variability coefficients in the
measuring range were less than 10%.
The first cortisol value directly after awakening on the
first day (T1) was considered as a basal indicator of cor-
tisol level. In addition, using formulas described by
Pruessner et al. [41], the area under the curve with re-
spect to the ground (AUCg) and with respect to the
increase (AUCi) were calculated based on the four
morning cortisol measures. The AUCg is an estimate of
the total cortisol secretion over the first hour of awaken-
ing; the AUCi is a measure of the dynamics of the corti-
sol awakening response related to the sensitivity of the
system and emphasizing the rate of change of the corti-
sol levels after awakening.
Evening cortisol was assessed as another basal indica-
tor of cortisol level. The mean of the two evening values
(at 10 p.m. and 11 p.m.) was used to reflect mean even-
ing cortisol; the correlation between the two evening
values was r = 0.55.
Diurnal slope was calculated by subtracting the value
at 11 p.m. (T6) from the sample at awakening (T1) and
dividing it by the number of hours in-between the two
samples, resulting in the decline in cortisol level per
hour. If the evening value at T6 was missing, the evening
value at 10 P.M. (T5) was used if available (n = 12).
The cortisol suppression ratio was calculated by the
cortisol value at awakening on the first day (T1) divided
by the cortisol value at awakening on the next day (T7)
after ingestion of 0.5 mg dexamethasone the evening
before.
Covariates
First, cortisol sampling characteristics were considered
because these have been associated with salivary cortisol
in NESDA [40]. The sampling factors comprised awak-
ening time, working on day of sampling (yes/no), month
of sampling (light months March through September vs.
dark months October through February), and ≤6 h sleep
(yes/no). In addition, basic potential confounders in-
cluded sociodemographic characteristics (age, sex, and
years of education).
A second set of covariates included lifestyle and dis-
ease factors as these have been previously associated
with both HPA-axis function and chronic pain. Body
mass index was calculated as weight in kilograms di-
vided by height in meters squared. Smoking was catego-
rized as never smoker, former smoker and current
smoker. Alcohol use was categorized as non-drinker,
mild/moderate drinker (1–21 glasses/week for men and
1–14 glasses/week for women), and heavy drinker (>21
glasses/week for men and >14 glasses/week for women)
[42]. Physical activity was assessed with the International
Physical Activity Questionnaire [43] and expressed in
1000 metabolic equivalent minutes per week. Number of
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lepsy, diabetes mellitus, osteoarthritis, stroke, cancer,
chronic lung disease, thyroid disease, liver disease, intes-
tinal disorders, and ulcers) were assessed by self-report.
Chronic diseases were considered present if persons had
received treatment.
A third set of covariates included lifetime diagnoses of
depressive and/or anxiety disorders and use of antide-
pressants. Lifetime diagnoses included both current (i.e.
in past six months) and prior diagnoses of depressive
disorders (major depressive disorder and dysthymia) and
anxiety disorders (panic disorder, agoraphobia, general-
ized anxiety disorder and social phobia) and were estab-
lished with the Composite International Diagnostic
Interview (WHO version 2.1), a widely accepted and re-
liable instrument that assesses mental disorders accord-
ing to DSM standards [44]. Medication use was assessed
based on drug container inspection of all drugs used in
the past month and classified according to the World
Health Organization (WHO) Anatomical Therapeutic
Chemical (ATC) classification [45]. Use of antidepressants
were considered because of their reported association with
cortisol level [46] and pain level [47]. Antidepressant
medication included tricyclic antidepressants [TCA; ATC
code N06AA], selective serotonin reuptake inhibitors
[SSRI; ATC code N06AB] and other antidepressant medi-
cations [ATC codes N06AF/AG/AX]) and were consid-
ered if frequently used (daily or >50% of the time).
Statistical analyses
Descriptive baseline characteristics were reported as
mean, median, or percentage across persons with chronic
pain and controls. Differences between groups were exam-
ined using independent-sample t tests for continuous vari-
ables, chi-square tests for dichotomous and categorical
variables, and Mann-Whitney U tests for non-normally
distributed variables.
Logistic regression analyses were performed to analyze
the association between cortisol measures and the pres-
ence of chronic pain (vs. controls). Also, a U-curved as-
sociation of cortisol with the presence of chronic pain
was considered by entering quadratic terms of cortisol
measures to the model also including the linear terms.
To examine whether cortisol measures were associated
with pain severity in subjects with chronic pain, separate
linear regression analyses were conducted with cortisol
measures as predictors and pain intensity and pain dis-
ability as outcome variables.
In all logistic and linear regression analyses, three
models were tested: (1) adjusted for cortisol sampling
factors and sociodemographic variables; (2) additionally
adjusted for lifestyle and disease factors, and; (3) add-
itionally adjusted for lifetime diagnoses of depressive or
anxiety disorders and use of antidepressants.Because depressive and anxiety disorders have previ-
ously been associated with hypercortisolemia [31], we
subsequently examined the association between cortisol
and chronic pain, free from any depression/anxiety ef-
fects. Therefore, we tested the possible moderating effect
of depressive and/or anxiety disorders on the association
between cortisol and chronic pain. Chronic pain subjects
without and chronic pain subjects with lifetime depres-
sive and anxiety disorders (LDA) were each compared
with control subjects without chronic pain and without
LDA by performing adjusted multinomial logistic regres-
sion analyses.
For all statistical tests, a probability level of less than
or equal to 5% was regarded as significant. The statistical
calculations were performed using SPSS, version 20.0.
Results
Baseline characteristics
Baseline characteristics of the study population are
shown in Table 1. In subjects with chronic multi-site
musculoskeletal pain, the mean days of pain in the prior
six months was 109.0 (SD = 69.9), the mean pain inten-
sity score was 52.3 (SD = 17.7) and the mean pain dis-
ability score was 38.1 (SD = 24.9). Compared to controls,
subjects with chronic pain differed in all cortisol sam-
pling factors, were significantly older, were more often
women, had less education, had a higher body mass
index, were more often current smokers, were more
often non-drinkers, had more chronic diseases, had
more often a current and a lifetime comorbid depressive
and/or anxiety disorder, and used more often antidepres-
sants (all p < 0.05). Regarding cortisol measures, diurnal
slope was significantly lower in the chronic pain group
in comparison to the control group. For the other corti-
sol measures, differences between subjects with and
without chronic pain were not significant in unadjusted
analyses.
HPA-axis function and the presence and severity of
chronic multi-site musculoskeletal pain
Table 2 reports the results of the adjusted logistic regres-
sion analyses, assessing the association between cortisol
measures and the presence of chronic multi-site muscu-
loskeletal pain. Lower cortisol levels at awakening were
associated with the presence of chronic pain after adjust-
ment for confounders. Lower evening cortisol levels
were associated with the presence of chronic pain after
adjustment for lifestyle and disease factors and after full
adjustment for depression and anxiety factors. The asso-
ciation between a flatter diurnal slope and the presence
of chronic pain was not significant after sociodemo-
graphic adjustment and after additional adjustment for
lifestyle and disease factors, but this association became
statistically significant after adjustment for depression
Table 1 Baseline characteristics*
Controls Chronic pain P† N~
(n = 654) (n = 471)
Pain
Days of pain in the prior 6 months 28.3 ± 49.1 109.0 ± 69.9 <0.001
Pain intensity 21.5 ± 14.7 52.3 ± 17.7 <0.001
Pain disability 9.4 ± 13.2 38.1 ± 24.9 <0.001
Cortisol sampling factors
Time of awakening 7:23 ± 1:07 7:34 ± 1:10 0.01
Working on day of sampling, % 67.2 48.5 <0.001
Sampling in month with more daylight, % 52.7 54.4 0.50
≤6 h sleep, % 21.0 37.3 <0.001
Sociodemographic factors
Age, years 43.3 ± 13.4 46.7 ± 11.8 <0.001
Women, % 56.7 73.5 <0.001
Education, years 13.1 ± 3.3 11.6 ± 3.3 <0.001
Lifestyle and disease factors
Body mass index, kg/m2 25.0 ± 4.2 26.2 ± 4.8 <0.001
Smoking, % 0.05
Never smoker 32.0 27.2
Former smoker 39.0 37.2
Current smoker 29.1 35.7
Alcohol use, % <0.001
Non-drinker 20.9 38.2
Mild/moderate drinker 66.2 50.7
Heavy drinker 12.8 11.0
Physical activity, 1000 MET min./week 3.6 ± 3.0 3.9 ± 3.1 0.06
Number of chronic diseases 0.6 ± 0.8 0.9 ± 0.9 <0.001
Depression and anxiety factors
Lifetime depressive or anxiety disorder, % <0.001
No disorder 40.4 12.7
Depressive disorder 19.0 16.8
Anxiety disorder 13.1 10.0
Comorbid depressive/anxiety disorder 27.5 60.5
Current depressive or anxiety disorder, % 35.9 67.5 <0.001
Antidepressant medication, % <0.001
No antidepressant 83.2 71.3
SSRI 10.9 20.0
TCA 2.1 2.3
Other antidepressant 3.8 6.4
Cortisol measures
At awakening, nmol/l, median [IQR] 15.88 [12.42-20.17] 15.48 [12.07-19.45] 0.10 1105
AUCg, nmol/l/h 19.0 ± 7.0 18.8 ± 6.7 0.55 1025
AUCi, nmol/l/h 1.9 ± 6.5 2.6 ± 6.2 0.09 1025
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Table 1 Baseline characteristics* (Continued)
Mean evening level, nmol/l, median [IQR] 4.68 [3.23-6.34] 4.90 [3.38-6.83] 0.07 1120
Diurnal slope, decline in nmol/l/h 0.77 ± 0.49 0.71 ± 0.39 0.05 1001
Cortisol suppression ratio, median [IQR] 2.43 [1.75-3.33] 2.35 [1.70-3.12] 0.23 1061
MET =metabolic equivalent; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
AUCg = area under the curve with respect to the ground; AUCi = area under the curve with respect to the increase.
*Values are mean ± SD unless otherwise indicated. †Based on independent-sample T test for continuous
variables, chi-square test for dichotomous and categorical variables and Mann-Whitney U test for non-normally distributed variables. ~N-values that vary from total
N = 1125 due to missings on individual cortisol measures.
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pression ratio, no statistically significant associations
with the presence of chronic pain were found.
To test for a possible U-curved association with the
presence of chronic pain, quadratic terms of cortisolTable 2 Associations* between cortisol measures and the
presence of chronic multi-site musculoskeletal pain
(n = 1125)
OR (95% CI) P
At awakening
Sociodemographica 0.86 (0.75, 0.98) 0.03
Lifestyle & diseaseb 0.83 (0.72, 0.95) 0.009
Depression and anxietyc 0.81 (0.70, 0.94) 0.006
AUCg
Sociodemographica 0.94 (0.83, 1.08) 0.40
Lifestyle & diseaseb 0.91 (0.79, 1.06) 0.23
Depression and anxietyc 0.89 (0.76, 1.04) 0.13
AUCi
Sociodemographica 1.10 (0.97, 1.26) 0.15
Lifestyle & diseaseb 1.12 (0.97, 1.30) 0.12
Depression and anxietyc 1.10 (0.94, 1.28) 0.25
Mean evening level
Sociodemographica 0.92 (0.80, 1.05) 0.21
Lifestyle & diseaseb 0.85 (0.72, 0.99) 0.04
Depression and anxietyc 0.85 (0.72, 1.00) 0.05
Diurnal slope
Sociodemographica 0.89 (0.77, 1.02) 0.10
Lifestyle & diseaseb 0.88 (0.76, 1.02) 0.10
Depression and anxietyc 0.85 (0.73, 0.99) 0.04
Cortisol suppression ratio
Sociodemographica 1.02 (0.89, 1.16) 0.80
Lifestyle & diseaseb 1.03 (0.90, 1.18) 0.69
Depression and anxietyc 1.04 (0.90, 1.20) 0.57
*Based on adjusted logistic regression analyses; OR per 1 SD increase;
At awakening: SD = 6.78, AUCg: SD = 6.87, AUCi: SD = 6.39, mean evening level:
SD = 3.43, diurnal slope: SD = 0.45, cortisol suppression ratio: SD = 1.58.
aAdjusted for awakening time, working on day of sampling, month of
sampling, ≤6 hours of sleep, age, sex, and years of education.
bAdditionally adjusted for body mass index, smoking, alcohol intake, physical
activity, and chronic diseases; cadditionally adjusted for lifetime depressive/
anxiety disorder and antidepressants.measures were examined. These adjusted logistic regres-
sion analyses revealed that the quadratic term of diurnal
slope was significantly associated with the presence of
chronic pain (p = 0.05; all other p ≥ .15). Therefore, quin-
tiles of diurnal slope were created and entered as predic-
tors in adjusted logistic regression analyses with chronic
pain as outcome. No evidence was found for a U-curved
association when the lowest and highest quintile of diur-
nal slope were compared with intermediate categories
(lowest quintile: OR = 1.09, p = 0.65; highest quintile:
OR = 0.72, p = 0.08) (data not shown).
Table 3 reports the associations between cortisol
measures and pain intensity and pain disability among
subjects with chronic pain (n = 471). No significant asso-
ciations were found. Additional analyses considering
chronic pain subjects without lifetime depression and
anxiety also indicated no associations for cortisol with
pain severity (data of additional analyses not tabulated).
HPA-axis function and chronic multi-site musculoskeletal
pain without/with depression and anxiety
This study found hypoactive HPA-axis function in
chronic multi-site musculoskeletal pain (Table 2), while
depressive and some types of anxiety disorders have pre-
viously been associated with hypercortisolemia [31,32],
also in the NESDA study [33,34]. To further examine
possible moderating effects, we subsequently tested
whether depressive and/or anxiety disorders mask the
association between cortisol measures and the presence
of chronic pain. Adjusted multinomial logistic regression
analyses were performed for chronic pain subjects with-
out lifetime depressive and/or anxiety disorders (n = 60)
and chronic pain subjects with lifetime depressive and/
or anxiety disorders (n = 411) separately compared to
control subjects (without chronic pain and without life-
time depressive and/or anxiety disorders; n = 264) (see
Table 4). These analyses indicated that lower cortisol at
awakening, lower AUCg and a flatter diurnal slope were
significantly associated with higher odds of chronic pain
in persons without depressive and anxiety disorders.
Additional adjustment for lifestyle and disease factors
hardly affected these results. In contrast, none of the
cortisol measures were significantly associated with
chronic pain with depressive and/or anxiety disorders.
Table 3 Associations* between cortisol measures and
pain intensity and pain disability in subjects with chronic
multi-site musculoskeletal pain (n = 471)
Pain intensity Pain disability
Beta P Beta P
At awakening
Sociodemographica 0.05 0.32 0.01 0.86
Lifestyle & diseaseb 0.04 0.42 0.00 0.94
Depression and anxietyc 0.02 0.72 -0.01 0.86
AUCg
Sociodemographica 0.01 0.86 -0.05 0.28
Lifestyle & diseaseb -0.01 0.92 -0.05 0.34
Depression and anxietyc -0.03 0.54 -0.06 0.22
AUCi
Sociodemographica -0.05 0.32 -0.06 0.21
Lifestyle & diseaseb -0.06 0.18 -0.06 0.23
Depression and anxietyc -0.07 0.15 -0.06 0.23
Mean evening level
Sociodemographica 0.00 0.99 -0.03 0.59
Lifestyle & diseaseb -0.01 0.80 -0.01 0.81
Depression and anxietyc -0.01 0.79 -0.01 0.93
Diurnal slope
Sociodemographica 0.06 0.21 0.03 0.61
Lifestyle & diseaseb 0.05 0.29 0.01 0.78
Depression and anxietyc 0.03 0.57 0.00 0.94
Cortisol suppression ratio
Sociodemographica 0.00 0.98 0.02 0.68
Lifestyle & diseaseb 0.01 0.82 0.02 0.67
Depression and anxietyc 0.01 0.89 0.01 0.76
*Based on adjusted linear regression analyses; aadjusted for awakening time,
working on day of sampling, month of sampling, ≤6 hours of sleep, age, sex,
and years of education; badditionally adjusted for body mass index, smoking,
alcohol intake, physical activity, and chronic diseases; cadditionally adjusted for
lifetime depressive/anxiety disorder and antidepressants.
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depressive and/or anxiety disorders to chronic pain sub-
jects with depressive and/or anxiety disorders, a signifi-
cant difference for cortisol at awakening was found after
sociodemographic adjustment. This difference was only
marginally significant after adjustment for lifestyle and
disease. In addition, AUCg and diurnal slope signifi-
cantly differed between chronic pain subjects without
and with depressive and/or anxiety disorders before and
after adjustment for confounders.
Discussion
The main objective of the current cross-sectional study
was to investigate the association between HPA-axis dys-
regulation and the presence and severity of chronic
multi-site musculoskeletal pain. Chronic pain subjects inthis study show lower awakening cortisol levels, lower
evening levels and a blunted diurnal slope compared to
controls. These associations appeared to be partly masked
by comorbid depressive and/or anxiety disorders, which
are typically accompanied by hypercortisolemia.
Our findings of hypocortisolemia and a blunted diur-
nal cortisol slope in subjects with chronic multi-site
musculoskeletal pain are in line with other studies that
reported a hypoactive HPA-axis in chronic pain condi-
tions [13,19,21-24]. This blunting of the HPA-axis has
been proposed to occur after prolonged exposure to
stress [14]. During acute stress, the adrenal cortex pro-
duces more cortisol which in turn inhibits the secretion
of corticotrophin-releasing hormone (CRH) from the
hypothalamus and adrenocorticotropic hormone (ACTH)
from the pituitary to eventually normalize cortisol release
and maintain body homeostasis [14]. Before the develop-
ment of chronic pain, the HPA-axis may start hyperactive,
but after long-term hyperactivity the stress system may
reach a state of exhaustion and the HPA-axis turns to a
state of hypoactivity [48]. This hypoactive state of the
HPA-axis is also suggested by hyperreactivity of ACTH
after CRH infusion suggesting up-regulation of pituitary
CRH receptors due to a hypoactive state of endogeneous
CRH and hypocortisolemia [24,49,50].
Morning hypocortisolemia and a blunted diurnal corti-
sol slope were most clearly present in chronic pain sub-
jects without lifetime depressive and/or anxiety disorders.
Depression and specific types of anxiety disorders have
often been associated with hypercortisolemia [31,32,51],
as also previously demonstrated in the NESDA study (i.e.,
increased cortisol awakening response for both current
and remitted major depressive disorder and panic disorder
with agoraphobia [33,34]). Several other studies outlined a
distinction between HPA-axis hyperactivity in depression
and HPA-axis hypoactivity in chronic pain [13,52], which
suggests distinct biological processes in psychological dis-
orders and pain conditions. Additional analyses in our
sample indicate that both a current diagnosis and a prior
history of depressive and/or anxiety disorders mask hypo-
cortisolemia in chronic multi-site musculoskeletal pain.
Altered morning cortisol level may represent a trait rather
than a state which reflects biological vulnerability or a bio-
logical scar resulting from depression and anxiety [34].
Although the current study did not measure nocturnal
cortisol levels, hypocortisolemia at awakening might in-
dicate reduced cortisol secretion during the late phase of
sleep or differences in frequency of cortisol peaks over-
night [17,53]. A previous longitudinal study found non-
restorative sleep (waking feeling unrefreshed) to be asso-
ciated with the resolution of chronic widespread pain
[54]. However, the role of sleep-related disturbances on
HPA-axis perturbations in chronic multi-site musculo-
skeletal pain warrants further research.
Table 4 Associations* between cortisol measures and the presence of chronic multi-site musculoskeletal pain in persons
without and with a lifetime depressive and/or anxiety disorder
Chronic pain without LDA (n = 60) vs.
controls (n = 264)
Chronic pain with LDA (n = 411) vs.
controls (n = 264)
Chronic pain with LDA vs.
chronic pain without LDAc
OR (95% CI) P OR (95% CI) P P
At awakening
Sociodemographica 0.67 (0.47, 0.94) 0.02 0.94 (0.79, 1.12) 0.50 0.04
Lifestyle & diseaseb 0.66 (0.46, 0.93) 0.02 0.90 (0.74, 1.09) 0.27 0.07
AUCg
Sociodemographica 0.61 (0.43, 0.89) 0.009 1.04 (0.86, 1.25) 0.68 0.003
Lifestyle & diseaseb 0.62 (0.42, 0.90) 0.01 0.96 (0.79, 1.18) 0.72 0.02
AUCi
Sociodemographica 0.95 (0.69, 1.32) 0.77 1.15 (0.96, 1.38) 0.14 0.24
Lifestyle & diseaseb 1.00 (0.71, 1.40) 0.99 1.11 (0.91, 1.36) 0.30 0.51
Mean evening level
Sociodemographica 0.89 (0.61, 1.29) 0.53 0.96 (0.79, 1.17) 0.68 0.67
Lifestyle & diseaseb 0.93 (0.64, 1.33) 0.68 0.82 (0.66, 1.02) 0.07 0.49
Diurnal slope
Sociodemographica 0.71 (0.49, 1.01) 0.06 1.03 (0.85, 1.24) 0.80 0.03
Lifestyle & diseaseb 0.70 (0.49, 0.99) 0.05 1.04 (0.85, 1.27) 0.69 0.02
Cortisol suppression ratio
Sociodemographica 0.89 (0.65, 1.21) 0.44 0.95 (0.81, 1.11) 0.51 0.67
Lifestyle & diseaseb 0.86 (0.62, 1.19) 0.36 0.99 (0.83, 1.17) 0.87 0.40
LDA = Lifetime depressive and/or anxiety disorder.
*Based on adjusted multinomial logistic regression analyses using persons without chronic pain and without LDA as the reference group (n = 264); OR per 1 SD
increase; At awakening: SD = 6.78, AUCg: SD = 6.87, AUCi: SD = 6.39, mean evening level: SD = 3.43, diurnal slope: SD = 0.45, cortisol suppression ratio: SD = 1.58.
aAdjusted for awakening time, working on day of sampling, month of sampling, ≤6 hours of sleep, age, sex, years of education; badditionally adjusted for body
mass index, smoking, alcohol intake, physical activity, and chronic diseases; cbased on the same multinomial logistic regression analyses using chronic pain
without LDA as the reference group.
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sample of subjects with chronic multi-site musculoskel-
etal pain compared to controls, which is in contrast with
elevated evening levels found in previous studies in pa-
tients with fibromyalgia with a smaller sample size than
the current study [16,17]. However, in support of our
findings, a cross-sectional study by McBeth et al.
showed that a lower saliva cortisol score, composed of
morning and evening cortisol levels, was associated with
chronic widespread pain and being psychologically at
risk of chronic widespread pain [25].
No significant associations with chronic multi-site mus-
culoskeletal pain were found for the dynamic of the corti-
sol awakening response (AUCi) and post-dexamethasone
cortisol levels, which is in contrast to a previous study that
demonstrated non-suppression of the HPA-axis in 131
subjects with chronic widespread pain by elevated serum
cortisol levels after a 0.25 mg dexamethasone suppression
test [25]. This opposite finding might be explained by het-
erogeneity of samples or measurement differences, e.g. in
the assessment of pain, depression, anxiety and cortisol
[55]. Moreover, as also suggested by the results of ourstudy, adjusting for the effects of psychological distress
might attenuate the association between post-stress corti-
sol levels and chronic multi-site musculoskeletal pain [25].
A previous study found that hypocortisolemia was
present in women with fibromyalgia but not in men
[56]. Our study could not examine gender differences in
the association between cortisol and chronic pain, free
of the effects of psychopathology, because group sample
sizes would become too small.
In contrast to the hypothesis that HPA-axis dysregula-
tion was associated with pain severity, no associations
with HPA-axis function were found for both pain inten-
sity and pain disability among persons with chronic
multi-site musculoskeletal pain. This might suggest that
once hypocortisolemia is present in subjects with
chronic multi-site musculoskeletal pain, hypoactivity of
the HPA-axis does not further impact pain severity. Pro-
spective studies should further investigate the possible
differential role for hypocortisolemia in the onset and
perpetuation of chronic multi-site musculoskeletal pain.
Several methodological issues related to this study
should be noted. First, our cross-sectional study design
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Longitudinal studies are needed to examine whether
HPA-axis hypoactivity is the cause or the consequence
of chronic multi-site musculoskeletal pain and its corre-
lates such as sleep disturbance, inactivity, and low fit-
ness. Second, previous studies mostly examined chronic
widespread pain using diagnostic criteria by Wolfe et al.
[57] in which participants need to have axial and bilat-
eral pain above and below the waist. To best reflect this
definition of axial and bilateral pain [57], we classified
persons as having chronic multi-site musculoskeletal
pain if they had pain in (one or more of) the extremities,
the back AND the neck. Using our criteria of chronic
pain, we may have included patients with milder pain
complaints than previous studies that investigated fibro-
myalgia patients with chronic widespread pain in all four
body quadrants. However, chronic multi-site pain can
occur without meeting the classification criteria for
chronic widespread pain and therefore setting broader pa-
rameters for studying biological mechanisms in chronic
pain patients might be useful [4,5]. Third, chronic pain is
defined as pain for ≥3 months, whereas we used the CPG
that assesses the number of days in pain in the prior
6 months. Our subjects with chronic multi-site mus-
culoskeletal pain had on average 109 days of pain
(~3.5 months) in the most painful location in the prior
6 months. Additional analyses considering only chronic
pain subjects with pain for ≥3 months showed similar
odds ratio’s for cortisol at awakening, AUCg and diurnal
slope (as compared to Table 4). Therefore, it appears un-
likely that the criterion to define chronic pain explains our
findings. Fourth, to increase sample size, we included per-
sons with grade I on the CPG and pain in ≤2 locations in
the control group. Comparisons with a more strict control
group might elucidate even stronger associations. How-
ever, chronic pain in 1 or 2 locations is quite common in
the population [2] which suggests that our control group
resembled the general population and even improved the
generalizability of our findings. Fifth, the ambulatory corti-
sol measures used in our study might not have been as
rigorous as those in laboratory settings, because we did
not have full control over the sample collection and the
ingestion of the 0.5 mg dexamethasone. However, in a
pilot study among 47 respondents, 90% showed detectable
dexamethasone levels in the saliva sample the next morn-
ing at awakening [40] suggesting that non-compliance
with dexamethasone ingestion is unlikely to explain our
findings. Finally, HPA-axis function fluctuates from day-
to-day while we only sampled cortisol on one day.
Although the median time lap between the baseline inter-
view and cortisol sampling was only 9 (IQR: 5-22) days,
subjects did not report current mood or other state effects
on the day of sampling. Nonetheless, we adjusted for
current mood disorders in our analyses, which are highlycorrelated with current mood. This study also has clear
strengths as compared to previous studies in the field, in-
cluding its large sample size, a detailed assessment of
HPA-axis functioning and the possibility to control for
various confounders. Because a large part of this study
sample consisted of persons with depressive and/or anx-
iety disorders, the unique possibility was provided to
closely examine the association between HPA-axis func-
tion and chronic multi-site musculoskeletal pain while
taking into account the possible effects of depressive and
anxiety disorders which are often present in persons with
chronic pain [34,40].Conclusions
The present study indicates hypocortisolemia in chronic
multi-site musculoskeletal pain, which appears to be
partly masked by the presence of comorbid depressive
and/or anxiety disorders. Future studies should take psy-
chopathology into account when examining HPA-axis
function in chronic multi-site musculoskeletal pain.
However, whether hypocortisolemia is also associated
with the onset or perpetuation of chronic multi-site
musculoskeletal pain should be further examined in lon-
gitudinal analyses.
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